Slow Sodium
PreclinicalSmall molecule
Slow Sodium is one of 9 small molecule programs targeting Endothelial Function. It is currently in Preclinical.
2
Indications
3
Total Trials
0
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
9 competitors in Endothelial Function
#DrugCompanyPhaseTrials
1Nulojix
Bristol-Myers SquibbApproved
Estrace
Novo NordiskApproved
Miochol
BBausch Health Americas, Inc.
Phase 1
Azulfidine
PfizerPreclinical
Slow Sodium
SSt George's, University of London
Preclinical
Viagra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
L-NG-Monomethyl Arginine (l-NMMA)
EEmory University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Slow Sodium. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details